- Home
- EYEN
EYEN
Eyenovia Inc.
as 11-15-2024 4:00pm EST
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 38.2M | IPO Year: | 2018 |
| Target Price: | $12.00 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.09 - $2.57 | Next Earning Date: | 11-12-2024 |
| Revenue: | $31,832 | Revenue Growth: | 2557.10% |
| Revenue Growth (this year): | 50943.04% | Revenue Growth (next year): | 397.57% |
Stock Insider Trading Activity of Eyenovia Inc. (EYEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rowe Michael M | EYEN | Chief Executive Officer | Aug 28 '24 | Buy | $0.52 | 27,071 | $14,076.92 | 109,998 | |
| Rowe Michael M | EYEN | Chief Executive Officer | Aug 26 '24 | Buy | $0.57 | 50,000 | $28,500.00 | 109,998 |
Latest Eyenovia Inc. News
EYEN Breaking Stock News: Dive into EYEN Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Sector Update: Health Care Stocks Slide Late Afternoon
MT Newswires
2 days ago
Sector Update: Health Care
MT Newswires
2 days ago
Update: Eyenovia Considers 'Options' After Dispensing Platform Study Fails to Meet Target -- Shares Drop
Benzinga
2 days ago
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
MT Newswires
2 days ago
Sector Update: Health Care Stocks Decline Premarket Friday
MT Newswires
2 days ago
Top Premarket Decliners
MT Newswires
2 days ago
Eyenovia to Consider 'Strategic Options' After Phase 3 Study Fails to Meet Primary Endpoint
Simply Wall St.
2 days ago
Eyenovia Third Quarter 2024 Earnings: Misses Expectations
Compare EYEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYEN Eyenovia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.